NPI: 1164748273 · MIAMI, FL 33183 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 04/14/2010
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 04/14/2010 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 9,160 | $1.34M |
| 2019 | 17,204 | $2.84M |
| 2020 | 12,243 | $1.81M |
| 2021 | 14,111 | $772K |
| 2022 | 4,332 | $303K |
| 2023 | 776 | $76K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 21,478 | 1,185 | $2.57M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 19,421 | 849 | $2.15M |
| J1270 | Injection, doxercalciferol, 1 mcg | 6,831 | 465 | $1.14M |
| A4657 | Syringe, with or without needle, each | 1,815 | 870 | $353K |
| J1756 | Injection, iron sucrose, 1 mg | 2,438 | 364 | $264K |
| 83540 | 1,277 | 804 | $141K | |
| 83550 | 1,275 | 803 | $135K | |
| 82728 | 884 | 568 | $101K | |
| 85048 | 780 | 489 | $99K | |
| 85041 | 784 | 493 | $99K | |
| 83970 | 585 | 342 | $70K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 209 | 89 | $18K |
| 82108 | 32 | 24 | $7K | |
| 82746 | 17 | 12 | $4K |